[go: up one dir, main page]

PE20050950A1 - Derivados de triazol sustituidos como antagonistas de oxitocina - Google Patents

Derivados de triazol sustituidos como antagonistas de oxitocina

Info

Publication number
PE20050950A1
PE20050950A1 PE2004000912A PE2004000912A PE20050950A1 PE 20050950 A1 PE20050950 A1 PE 20050950A1 PE 2004000912 A PE2004000912 A PE 2004000912A PE 2004000912 A PE2004000912 A PE 2004000912A PE 20050950 A1 PE20050950 A1 PE 20050950A1
Authority
PE
Peru
Prior art keywords
alkyl
nr7r8
metoxypyridin
metoximethyl
nr7c
Prior art date
Application number
PE2004000912A
Other languages
English (en)
Inventor
David Ellis
Christopher Ronald Smith
Alan Daniel Brown
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050950A1 publication Critical patent/PE20050950A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS 1,2,4-TRIAZOLES SUSTITUIDOS DE FORMULA (I), EN DONDE V, W, X E Y SON INDEPENDIENTEMENTE, C-R6 O N; Z ES C-H O N; R1 ES FENILO SUSTITUIDO CON DOS O MAS SUSTITUYENTES COMO HALOGENO, ALQUILO(C1-C6), ALCOXI(C1-C6), CIANO, C(O)NR7R8, NR7R8, NR7C(O)R10 Y N[C(O)R10]2; O PIRIDINILO O N-OXIDO DE PIRIDINILO CADA UNO SUSTITUIDOS; R2 ES H, OH, OR9, NR7R8, NR7C(O)R10 Y N[C(O)R10]2, HETEROCICLO DE 5 A 7 MIEMBROS O ALQUILO(C1-C6), OPCIONALMENTE SUSTITUIDOS; R3 ES H, ALQUILO(C1-C6); R4 ES H, ALQUILO(C1-C6) Y OR9; R5 ES HALO, ALQUILO(C1-C6), ALCOXI(C1-C6), NR7R8, NR7C(O)R10 Y N[C(O)R10]2. SON COMPUESTOS PREFERIDOS: 2-(4-FLUORO-2-METILFENIL)-5-(5-METOXIMETIL-4-(6-METOXIPIRIDIN-3-IL)-4H-[1,2,4]TRIAZOL-3-IL)-PIRIDINA, 2-(2,3-DIMETOXIFENIL-5-{5-METOXIMETIL-4-(6-METOXIPIRIDIN-3-IL)-4H-[1,2,4]TRIAZOL-3-IL]-PIRAZINA, 2-(4-CIANO-2-METILFENIL)-5-[5-METOXIMETIL-4-(6-METOXIPIRIDIN-3-IL)4H-[1,2,4]TRIAZOL-3-IL]-PIRAZINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DE OXITOCINA POR LO QUE SON UTILES EN EL TRATAMIENTO DE DISFUNCION SEXUAL, PARTICULARMENTE LA EYACULACION PRECOZ
PE2004000912A 2003-09-22 2004-09-20 Derivados de triazol sustituidos como antagonistas de oxitocina PE20050950A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
PE20050950A1 true PE20050950A1 (es) 2005-11-11

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000912A PE20050950A1 (es) 2003-09-22 2004-09-20 Derivados de triazol sustituidos como antagonistas de oxitocina

Country Status (12)

Country Link
EP (1) EP1673355A1 (es)
JP (1) JP2007505888A (es)
AR (1) AR045791A1 (es)
BR (1) BRPI0414663A (es)
CA (1) CA2539297C (es)
MX (1) MXPA06003158A (es)
NL (1) NL1027084C2 (es)
PA (1) PA8613001A1 (es)
PE (1) PE20050950A1 (es)
TW (1) TW200526606A (es)
UY (1) UY28524A1 (es)
WO (1) WO2005028452A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
CA2586612C (en) * 2004-11-18 2016-10-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2602383A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
WO2010033977A2 (en) 2008-09-22 2010-03-25 Cayman Chemical Company Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP3501533B1 (en) 2014-12-22 2025-07-09 Ferring B.V. Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies
CN108884071B (zh) * 2016-12-21 2021-05-14 江苏恒瑞医药股份有限公司 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用
EP3564231A4 (en) 2016-12-28 2020-08-12 Jiangsu Hengrui Medicine Co., Ltd. AZABICYCLO-SUBSTITUTE TRIAZOLE DERIVATIVE, METHOD OF PREPARATION AND APPLICATION IN MEDICINE
CN111094272B (zh) * 2018-06-20 2022-05-27 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
JP2022042278A (ja) * 2020-09-02 2022-03-14 国立大学法人浜松医科大学 化合物又はその塩及び中枢オキシトシン受容体イメージング剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
CA2409819C (en) * 2000-05-19 2009-09-15 Yamanouchi Pharmaceutical Co., Ltd. Triazole derivatives
EP1273580B1 (en) * 2001-07-05 2005-06-15 Pfizer Products Inc. Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents
IL162615A0 (en) * 2001-12-20 2005-11-20 Applied Research Systems Triazole derivatives, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2005028452A9 (en) 2005-07-21
TW200526606A (en) 2005-08-16
JP2007505888A (ja) 2007-03-15
NL1027084C2 (nl) 2006-01-24
MXPA06003158A (es) 2006-06-05
BRPI0414663A (pt) 2006-11-21
UY28524A1 (es) 2005-04-29
PA8613001A1 (es) 2005-08-04
WO2005028452A1 (en) 2005-03-31
NL1027084A1 (nl) 2005-03-24
EP1673355A1 (en) 2006-06-28
CA2539297A1 (en) 2005-03-31
CA2539297C (en) 2010-07-20
AR045791A1 (es) 2005-11-16

Similar Documents

Publication Publication Date Title
PE20050950A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20051141A1 (es) Inhibidores de la polimerasa viral
PE20060010A1 (es) 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
PE20030200A1 (es) Bencimidazol como inhibidores de las map quinasas
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20131377A1 (es) Triazina-oxadiazoles
PE20051051A1 (es) Compuestos de triazol como antagonistas de la vasopresina
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
PE20091527A1 (es) Derivados de piridazinona
AR022019A1 (es) Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen
MA31419B1 (fr) Derives de pyridine
PE20080139A1 (es) Compuestos de pirrolotriazina anilina como inhibidores de cinasa
PE20051047A1 (es) COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE
PE20080545A1 (es) Isoxazolinas insecticidas
PE20060316A1 (es) Derivados de prolina como inhibidores de dipeptidil peptidasa-iv
PE20081850A1 (es) Derivados ciclizados como inhibidores de la eg-5
JP2005525324A5 (es)
PE20080952A1 (es) Amidas azociclicas fungicidas
PE20050346A1 (es) Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2)
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
PE20110991A1 (es) Compuestos de fenil-piridazinona-pirazol-fenilo como inhibidores de pde

Legal Events

Date Code Title Description
FD Application declared void or lapsed